Latest Blood disorders Stories

Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock

2012-05-24 06:28:41

SAN DIEGO, May 24, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $50 million in additional equity funding from existing investor, Leucadia National Corporation. This funding was made upon the exercise of Series G preferred stock warrants previously held by Leucadia and brings the total funding raised by the...

Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association

2012-05-22 02:26:24

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands. The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the...

Blood Matters: For the 17th Year, Thousands of Hematologists Meet in Amsterdam, June 14-17, 2012

2012-05-21 02:24:45

AMSTERDAM, May 21, 2012 /PRNewswire/ -- 3rd Invitation to 17th Congress of EHA - European Hematology Association The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 17th Congress of EHA. More than 9,000 participants from around the world are expected at the upcoming Congress at the RAI Congress Center in Amsterdam from June 14-17, 2012. About the EHA Annual Congress: The...

/C O R R E C T I O N -- Amgen/

2012-05-18 14:20:40

In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012 by Amgen over PR Newswire, we are advised by the company that the third paragraph now includes additional safety information. The complete, corrected release follows: Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or...

Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting

2012-05-17 10:25:58

WOODCLIFF LAKE, N.J., May 17, 2012 /PRNewswire/ -- Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and their families affected by cancer. "Our human health care mission is to...

Phase 1 Trial Showed Encouraging Results In Children With Cancer

2012-05-17 12:14:34

Children's Hospital of Philadelphia researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study...

Experimental Drug May Help Elderly With CLL

2012-05-17 11:04:24

-Standard treatment for chronic leukemia is too harsh for many older patients. -Early clinical trials testing indicates that these patients respond well to the experimental drug ibrutinib. -This agent merits further testing as a first-line therapy for older chronic-leukemia patients. The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of older patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase...

Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology

2012-05-17 02:25:07

SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL. The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent...

Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

2012-05-16 14:22:36

THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness...

Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome

2012-05-15 02:28:09

PALO ALTO, Calif., May 15, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced two publications in the Journal of Hematology & Oncology. The first is "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raza, A., et al., Journal of Hematology & Oncology 2012, 5:18 doi:10.1186/1756-8722-5-18; 30 April 2012. The publication may be found...